ArticleOncoimmunology
S100A8
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- S100A8/A9 as a key player in colorectal cancer: from diagnosis to therapeutic targeting.Frontiers in pharmacology · 2026Review
- LeLISA: A New Lectin-Based Immunoassay for Evaluation of Mucinous and Serous Content in Pancreatic Cystic Neoplasms.Digestive diseases and sciences · 2025Article
- S100A8 regulated by estrogen improves injured endometrial epithelium reconstruction by promoting tight junction formation and stromal cell transformation.Scientific reports · 2025Article
- Article
- Correlation of gasdermin B staining patterns with prognosis, progression, and immune response in colorectal cancer.BMC cancer · 2024Article
- Article
- Serum Extracellular Vesicle Stratifin Is a Biomarker of Perineural Invasion in Patients With Colorectal Cancer and Predicts Worse Prognosis.Frontiers in oncology · 2022Article
- A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.Frontiers in medicine · 2022Article
- S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-β/USF2 axis in colorectal cancer.Cancer communications (London, England) · 2021Article
- Article
- Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection.British journal of cancer · 2020Article
- ARHGEF38 as a novel biomarker to predict aggressive prostate cancer.Genes & diseases · 2020Article
- Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: ISCancer science · 2020Article
- S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.Frontiers in immunology · 2020Article
- FAM83A as a Potential Biological Marker Is Regulated by miR-206 to Promote Cervical Cancer Progression Through PI3K/AKT/mTOR Pathway.Frontiers in medicine · 2020Article
- Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.Cancer immunology, immunotherapy : CII · 2019Article
- Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma.BMC medicine · 2019Article
- Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology.Analytical cellular pathology (Amsterdam) · 2019Review
- Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel.Clinical proteomics · 2019Article
- Clinicopathologic implications of CD8Cancer immunology, immunotherapy : CII · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene microarray and bioinformatic analysis showed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.